Ironwood Pharmaceuticals (IRWD) Expected to Post Earnings on Thursday

Ironwood Pharmaceuticals (NASDAQ:IRWD) is expected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Ironwood Pharmaceuticals to announce earnings of $0.3233 per share and revenue of $119.99 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The firm had revenue of $113.04 million for the quarter, compared to the consensus estimate of $114.84 million. Ironwood Pharmaceuticals had a negative return on equity of 58.38% and a net margin of 33.36%. On average, analysts expect Ironwood Pharmaceuticals to post $1.10 EPS for the current fiscal year and ($0.03) EPS for the next fiscal year.

Ironwood Pharmaceuticals Trading Up 1.2%

Shares of Ironwood Pharmaceuticals stock opened at $3.50 on Wednesday. The stock’s fifty day moving average price is $3.93 and its 200-day moving average price is $3.98. The firm has a market cap of $578.34 million, a P/E ratio of 4.44 and a beta of 0.25. Ironwood Pharmaceuticals has a 12 month low of $1.76 and a 12 month high of $5.78.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Jefferies Financial Group upgraded shares of Ironwood Pharmaceuticals to a “hold” rating in a report on Friday, September 25th. Zacks Research lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. Wall Street Zen cut shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 5th. Finally, Weiss Ratings raised shares of Ironwood Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $6.23.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a gastrointestinal-focused biopharmaceutical company headquartered in Boston, Massachusetts. The company discovers, develops, and commercializes medicines intended to treat disorders affecting the gastrointestinal tract, with an emphasis on conditions involving gut motility and visceral sensitivity.

Ironwood’s principal commercial product is Linzess (linaclotide), marketed in the United States in collaboration with AbbVie. Linzess is approved for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation.